Philippine Regulatory Developments in 2026: In Force, Deferred and Draft for Comments

1. Key takeaways

Three threads run through Philippine medical device regulation in 2026: the PMAS framework in AO No. 2025-0030 took effect on 6 May (with a 1-year transition period); the fourth deferral of the new fee schedule in AO No. 2024-0016 (120 working days); and several technical guidelines still at draft-for-comments stage (GMP, traceability and vigilance, device grouping). In addition, the source list and contract agreement requirements under AO No. 2024-0015 became mandatory from 1 January 2026.

• One framework is now in force, one fee reform is deferred again, and four technical guidelines remain drafts.
• The LTO documentation change is already live, having applied since 1 January 2026.
• The fee deferral is tied to a national energy emergency, which makes its end date unpredictable.
• Draft guidelines should not be turned into client commitments, although they are worth preparing for.
• Two widely circulated 2026 instruments could not be verified against the FDA website and are not relied on here.

2. Legal basis

The table below lists the instruments and events that define the 2026 position, in date order, with the status of each.

3. Expert insights

Insight 1: 2026 is the year the Philippine post-market system is built.

The entry into force of AO No. 2025-0030 is the single most significant item of the year. It institutionalises four obligations — records, complaints, adverse events and FSCA — in one instrument, while the supporting circulars that will detail them are still out for comment. The consequence is that companies must build the post-market system from the ground up during 2026 and 2027, rather than patch existing arrangements. Building from the ground up is different from incremental repair: it requires an owner, a documented architecture and a schedule, not a set of local fixes.

Insight 2: fee reform has a settled direction and an unsettled timetable.

AO No. 2024-0016 has now been deferred four times, and the fourth deferral is for the first time tied to the national energy emergency. At the March 2026 public consultation, the FDA explained that the relevant fee structure had not been adjusted for 25 years and that the increase would support additional staffing and service improvements, while stakeholders raised concerns about the size of the increase and its timing. The direction shows no sign of reversal and the timetable is highly uncertain, so companies should manage it as an event that could occur at any time rather than as a scheduled step in the budget cycle.

Insight 3: several technical guidelines are still in draft and should not support commitments.

Four guidelines are open for comment: GMP (PNS ISO 13485:2019), traceability and vigilance, device grouping, and clinical investigation. GRZAN’s position is consistent across all four: the draft content is worth preparing for, but it must not be written into commitments given to clients. In particular, if the grouping rule is finalised as drafted it could change the cost structure for multi-model products, but for the present, estimates should continue to assume one application per model.

Insight 4: two purported 2026 instruments are not accepted by GRZAN.

During verification, two sources appeared claiming that the FDA Philippines issued Circular No. 2026-017 in 2026 (requiring an ethics statement on training data for dental AI imaging devices) and Medical Devices Importation Circular No. 2026-07 (requiring imported ICU ventilators to pass PHILSAR-2026 tropical testing and to carry a bilingual interface). On checking, both appear only on content-generation sites, and no corresponding circular numbers or texts could be located on the FDA website; the descriptions also contain statements inconsistent with the existing Philippine regulatory framework. GRZAN does not accept them and this series does not cite them. If a client is told by a third party during a project that such a requirement exists, we will write to the CDRRHR to verify before responding.

4. Practical recommendations

• Maintain a regulatory tracking register with three columns: in force, deferred, draft for comments. Update it monthly so that the status of each instrument is visible at a glance.
• Complete PMAS system building within the transition period. Target self-assessment before May 2027.
• File submissions for core products during the deferral. Manage the window through a monthly review so that a change in the fee schedule does not catch the portfolio unprepared.
• Implement the LTO materials required from 1 January 2026. The source list and contract agreements should become routine documents rather than one-off submissions.
• Verify any unfamiliar new rule against the official source. Do not rely on a circular number that cannot be found in its original form on the FDA website.

5. Verification checklist

• □ AO 2025-0030 effective date confirmed as 6 May 2026
• □ Transition period end confirmed as May 2027
• □ AO 2024-0016 deferral status checked against the latest DOH department circular
• □ LTO mandatory materials in place since 1 January 2026
• □ Draft-for-comments list reviewed on the FDA website
• □ Source verification performed against the original text on the FDA website

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including the Philippines. Our team prepares CMDN/CMDR dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the FDA Philippines, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com